Recently Added Drugs
1. Adquey patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46792 | ACROTECH | NA |
Mar, 2028
(1 year, 10 months from now) | |
| US10588893 | ACROTECH | Ointment Containing An Oxazole Compound |
Dec, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2031 |
Drugs and Companies using DIFAMILAST ingredient
NCE-1 date: 12 February, 2030
Market Authorisation Date: 12 February, 2026
Treatment: Method of treating atopic dermatitis
Dosage: OINTMENT
More Information on Dosage
ADQUEY family patents
2. Artesunate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390442 | AMIVAS | NA |
Feb, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2025 |
| Orphan Drug Exclusivity(ODE-290) | May 26, 2027 |
Drugs and Companies using ARTESUNATE ingredient
NCE-1 date: 26 May, 2024
Market Authorisation Date: 26 May, 2020
Treatment: A method of treating malaria using micronized powder of crystalline artesunate prepared by sterilizing and filling the powder into a container at a relative humidity of 30 to 40%, mixing the powder wi...
Dosage: POWDER
More Information on Dosage
ARTESUNATE family patents
3. Arynta patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12582620 | AZURITY | NA |
Apr, 2040
(13 years from now) | |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Market Authorisation Date: 16 June, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ARYNTA family patents
4. Baxdela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12558349 | MELINTA | NA |
Mar, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2021
Market Authorisation Date: 19 June, 2017
Treatment: Treating an acute bacterial skin and skin structure infection (absssi) in an overweight or obese patient by intravenously (iv) administering 300mg of delafloxacin or a pharmaceutically acceptable salt...
Dosage: POWDER
More Information on Dosage
BAXDELA family patents
5. Bysanti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570453 | VANDA | Method Of Predicting A Predisposition To Qt Prolongation |
Mar, 2028
(1 year, 11 months from now) | |
| US9157121 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(3 years from now) | |
| US10563259 | VANDA | Method Of Treatment Based On Polymorphisms Of The Kcnq1 Gene |
Jul, 2030
(4 years from now) | |
| US8999638 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(4 years from now) | |
| US9074255 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(4 years from now) | |
| US9072742 | VANDA | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(4 years from now) | |
| US9074256 | VANDA | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(4 years from now) | |
| US9074254 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(5 years from now) | |
| US12478619 | VANDA | Method Of Treatment With Milsaperidone |
May, 2044
(18 years from now) | |
Drugs and Companies using MILSAPERIDONE ingredient
Market Authorisation Date: 20 February, 2026
Treatment: Method for acute treatment of manic or mixed episodes associated with bipolar i disorder in adults by administering milsaperidone to a patient by lowering the dose after determining that the patient h...
Dosage: TABLET
More Information on Dosage
BYSANTI family patents
6. Calquence patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11166951 | ASTRAZENECA | Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
| New Indication(I-817) | Nov 21, 2022 |
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-960) | Jan 16, 2028 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with venetoclax
Dosage: CAPSULE
How can I launch a generic of CALQUENCE before its drug patent expiration?
More Information on Dosage
CALQUENCE family patents
7. Calquence patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11166951 | ASTRAZENECA | Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
| New Indication(I-817) | Nov 21, 2022 |
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-960) | Jan 16, 2028 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with venetoclax
Dosage: TABLET
How can I launch a generic of CALQUENCE before its drug patent expiration?
More Information on Dosage
CALQUENCE family patents
8. Cobenfy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12558317 | BRISTOL MYERS | NA |
Oct, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 26, 2029 |
Drugs and Companies using TROSPIUM CHLORIDE; XANOMELINE TARTRATE ingredient
NCE-1 date: 26 September, 2028
Market Authorisation Date: 26 September, 2024
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
COBENFY family patents
9. Desmoda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12214010 | ETON | Desmopressin Oral Compositions |
Apr, 2044
(17 years from now) | |
| US12343372 | ETON | Desmopressin Oral Compositions |
Apr, 2044
(17 years from now) | |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 25 February, 2026
Treatment: Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients
Dosage: SOLUTION
More Information on Dosage
DESMODA family patents
10. Enbumyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12558330 | CORSTASIS | NA |
May, 2045
(19 years from now) | |
Drugs and Companies using BUMETANIDE ingredient
Market Authorisation Date: 12 September, 2025
Treatment: Intranasal bumetanide for the treatment of edema
Dosage: SPRAY
More Information on Dosage
ENBUMYST family patents
11. Erleada patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE50642 | JANSSEN | NA |
Sep, 2033
(7 years from now) | |
| US11723898 | JANSSEN | Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic Impairment |
Jan, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of non-metastatic castration-resistant prostate cancer (nmcrpc) by daily administration of 180 mg or 120 mg of apalutamide to patients receiving a gonadotropin-releasing hormone (gnrh) analo...
Dosage: TABLET
How can I launch a generic of ERLEADA before its drug patent expiration?
More Information on Dosage
ERLEADA family patents
12. Icotyde patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12552836 | JANSSEN | NA |
Jul, 2039
(13 years from now) | |
| US11845808 | JANSSEN | Peptide Inhibitors Of Interleukin-23 Receptor And Their Use To Treat Inflammatory Diseases |
Jan, 2041
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11939361 | JANSSEN | Compositions Of Peptide Inhibitors Of Interleukin-23 Receptor |
Nov, 2041
(15 years from now) | |
Drugs and Companies using ICOTROKINRA HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2026
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy
Dosage: TABLET
More Information on Dosage
ICOTYDE family patents
13. Imbruvica patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12551448 | PHARMACYCLICS | NA |
Mar, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 13 November, 2017
Market Authorisation Date: 16 February, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of IMBRUVICA before its drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
14. Inlexzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12576253 | JANSSEN | NA |
Dec, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 09, 2028 |
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 September, 2025
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
INLEXZO family patents
15. Iwilfin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12582625 | USWM | NA |
Feb, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 13, 2026 |
| Orphan Drug Exclusivity(ODE-462) | Dec 13, 2030 |
Drugs and Companies using EFLORNITHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2023
Treatment: Treatment to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (hrnb) who have demonstrated at least a partial response to prior multiagent, multimodality therapy...
Dosage: TABLET
More Information on Dosage
IWILFIN family patents
16. Juxtapid patent expiration
JUXTAPID's oppositions filed in EPO
JUXTAPID IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7932268 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(1 year, 3 months from now) | |
| US12472172 | CHIESI | Lomitapide For Use In Methods Of Treating Hyperlipidemia And Hypercholesterolemia In Pediatric Patients |
Jul, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 25 February, 2026
Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; Dosing regimen ...
Dosage: CAPSULE
More Information on Dosage
JUXTAPID family patents
17. Lynavoy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9040518 | GLAXOSMITHKLINE | Chemical Compounds |
Sep, 2031
(5 years from now) | |
Drugs and Companies using LINERIXIBAT ingredient
Market Authorisation Date: 17 March, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
LYNAVOY family patents
18. Mucinex 12hr Cold & Fever Multi-symptom patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278506 | RB HLTH | Pharmaceutical Formulation |
Oct, 2036
(10 years from now) | |
| US12257218 | RB HLTH | Pharmaceutical Formulation |
Oct, 2036
(10 years from now) | |
| US12370189 | RB HLTH | Pharmaceutical Formulation |
Oct, 2036
(10 years from now) | |
Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM ingredient
Market Authorisation Date: 22 December, 2025
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM family patents
19. Nuplazid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7732615 (Pediatric) | ACADIA | N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N′-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide And Its Tartrate Salt And Crystalline Forms |
Dec, 2028
(2 years from now) | |
|
US7601740 (Pediatric) | ACADIA | Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases |
Oct, 2030
(4 years from now) | |
|
US10517860 (Pediatric) | ACADIA | Combination Of Pimavanserin And Cytochrome P450 Modulators |
Sep, 2037
(11 years from now) | |
|
US10953000 (Pediatric) | ACADIA | Combination Of Pimavanserin And Cytochrome P450 Modulators |
Sep, 2037
(11 years from now) | |
|
US10449185 (Pediatric) | ACADIA | Formulations Of Pimavanserin |
Feb, 2039
(12 years from now) | |
|
US10646480 (Pediatric) | ACADIA | Formulations Of Pimavanserin |
Feb, 2039
(12 years from now) | |
|
US10849891 (Pediatric) | ACADIA | Formulations Of Pimavanserin |
Feb, 2039
(12 years from now) | |
|
US11452721 (Pediatric) | ACADIA | Formulations Of Pimavanserin |
Feb, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: NA
Dosage: TABLET; CAPSULE
How can I launch a generic of NUPLAZID before its drug patent expiration?
More Information on Dosage
NUPLAZID family patents
20. Ojjaara patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12576089 | GLAXOSMITHKLINE | NA |
Aug, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2028 |
| Orphan Drug Exclusivity(ODE-441) | Sep 15, 2030 |
Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 16 September, 2027
Market Authorisation Date: 15 September, 2023
Treatment: For the treatment of intermediate or high-risk myelofibrosis in subjects having a baseline platelet count of at least 100 billion/l but less than 150 billion/l and previously treated with a jak inhibi...
Dosage: TABLET
More Information on Dosage
OJJAARA family patents
21. Onyda Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12576032 | TRIS | NA |
Jul, 2041
(15 years from now) | |
Drugs and Companies using CLONIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 May, 2024
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ONYDA XR family patents
22. Opzelura patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12564593 | INCYTE | NA |
May, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 21, 2024 |
| New Indication(I-896) | Jul 18, 2025 |
| Pediatric Exclusivity(PED) | Jan 18, 2026 |
| New Patient Population(NPP) | Sep 18, 2028 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: NA
Dosage: CREAM
How can I launch a generic of OPZELURA before its drug patent expiration?
More Information on Dosage
OPZELURA family patents
23. Orladeyo patent expiration
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12590068 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| US12590069 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US12545645 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US12545646 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US12545647 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US12552750 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| Pediatric Exclusivity(PED) | Jun 11, 2029 |
| New Product(NP) | Dec 11, 2028 |
Drugs and Companies using BEROTRALSTAT DIHYDROCHLORIDE ingredient
NCE-1 date: 03 December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: NA
Dosage: CAPSULE; PELLETS
How can I launch a generic of ORLADEYO before its drug patent expiration?
More Information on Dosage
ORLADEYO family patents
24. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12569543 | NOVO NORDISK | NA |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Indication(I-961) | Jan 28, 2028 |
| New Indication(I-976) | Oct 17, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: Reduction of the risk of major adverse cardiovascular events in subjects with type 2 diabetes mellitus and cardiovascular disease
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before its drug patent expiration?
More Information on Dosage
OZEMPIC family patents
25. Pemazyre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12552792 | INCYTE | NA |
Oct, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-899) | Aug 26, 2025 |
| Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: NA
Dosage: TABLET
How can I launch a generic of PEMAZYRE before its drug patent expiration?
More Information on Dosage
PEMAZYRE family patents
26. Phenylephrine Hydrochloride In 0.9% Sodium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12564561 | DR REDDYS | NA |
Aug, 2044
(18 years from now) | |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE family patents
27. Pylarify Truvu patent expiration
PYLARIFY TRUVU's oppositions filed in EPO
Can you believe PYLARIFY TRUVU received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487129 | APHELION | Heterodimers of glutamic acid |
Nov, 2027
(1 year, 6 months from now) | |
| US12070513 | APHELION | PSMA-binding agents and uses thereof |
Jul, 2029
(3 years from now) | |
| US9861713 | APHELION | PSMA-binding agents and uses thereof |
Jul, 2029
(3 years from now) | |
| US8778305 | APHELION | PSMA-binding agents and uses thereof |
Sep, 2030
(4 years from now) | |
| US10947197 | APHELION | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(11 years from now) | |
| US11851407 | APHELION | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
Jun, 2037
(11 years from now) | |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
Market Authorisation Date: 06 March, 2026
Treatment: Positron emission tomography (pet) of prostate-specific membrane antigen (psma) positive lesions in men with prostate cancer
Dosage: SOLUTION
More Information on Dosage
PYLARIFY TRUVU family patents
28. Radicava Ors patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12569469 | KK BCJ 94 | NA |
Nov, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 12, 2025 |
| Orphan Drug Exclusivity(ODE-144) | May 12, 2029 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis by administering a liquid edaravone composition relative to the timing and type of food consumption
Dosage: SUSPENSION
How can I launch a generic of RADICAVA ORS before its drug patent expiration?
More Information on Dosage
RADICAVA ORS family patents
29. Revuforj patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12564590 | SYNDAX | NA |
Dec, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2029 |
| Orphan Drug Exclusivity(ODE-502) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-504) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-505) | Nov 15, 2031 |
Drugs and Companies using REVUMENIB CITRATE ingredient
NCE-1 date: 15 November, 2028
Market Authorisation Date: 15 November, 2024
Treatment: Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older
Dosage: TABLET
More Information on Dosage
REVUFORJ family patents
30. Romvimza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12582655 | DECIPHERA | NA |
Dec, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2030 |
Drugs and Companies using VIMSELTINIB ingredient
NCE-1 date: 14 February, 2029
Market Authorisation Date: 14 February, 2025
Treatment: Treatment of tenosynovial giant cell tumor
Dosage: CAPSULE
More Information on Dosage
ROMVIMZA family patents
31. Technegas Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7722856 | CYCLOMEDICA | Process For The Production Of A Radioactive Aerosol |
Feb, 2031
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 29, 2026 |
Drugs and Companies using TECHNETIUM TC-99M LABELED CARBON ingredient
Market Authorisation Date: 29 September, 2023
Treatment: Technegas (kit for the preparation of technetium tc 99m labeled carbon inhalation aerosol), for oral inhalation use
Dosage: AEROSOL
More Information on Dosage
TECHNEGAS KIT family patents
32. Tirosint patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12564565 | IBSA | NA |
Sep, 2044
(18 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 01 August, 2007
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of TIROSINT before its drug patent expiration?
More Information on Dosage
TIROSINT family patents
33. Tirosint-sol patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12564565 | IBSA | NA |
Sep, 2044
(18 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 15 December, 2016
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of TIROSINT-SOL before its drug patent expiration?
More Information on Dosage
TIROSINT-SOL family patents
34. Vafseo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12569474 | AKEBIA | NA |
Jun, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2029 |
Drugs and Companies using VADADUSTAT ingredient
NCE-1 date: 27 March, 2028
Market Authorisation Date: 27 March, 2024
Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months
Dosage: TABLET
More Information on Dosage
VAFSEO family patents
35. Vanrafia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12582631 | NOVARTIS | NA |
Mar, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2030 |
Drugs and Companies using ATRASENTAN HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2029
Market Authorisation Date: 02 April, 2025
Treatment: Treatment of primary immunoglobulin a nephropathy (igan)
Dosage: TABLET
More Information on Dosage
VANRAFIA family patents
36. Vigafyde patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12576054 | PYROS | NA |
Jun, 2043
(17 years from now) | |
Drugs and Companies using VIGABATRIN ingredient
Market Authorisation Date: 17 June, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VIGAFYDE family patents
37. Vtama patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12569453 | ORGANON | NA |
Dec, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2027 |
| New Indication(I-956) | Dec 12, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 23 May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
Dosage: CREAM
More Information on Dosage
VTAMA family patents
38. Wegovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12569543 | NOVO NORDISK | NA |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Dec 22, 2028 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Indication(I-973) | Aug 15, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Reduction of the risk of major cardiovascular events in subjects with cardiovascular disease and either obesity or overweight
Dosage: SOLUTION
How can I launch a generic of WEGOVY before its drug patent expiration?
More Information on Dosage
WEGOVY family patents
39. Wegovy Hd patent expiration
WEGOVY HD's oppositions filed in EPO
WEGOVY HD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129343 | NOVO NORDISK | Acylated GLP-1 compounds |
Dec, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9764003 | NOVO NORDISK | Use of long-acting GLP-1 peptides |
Jun, 2033
(7 years from now) | |
| US12569543 | NOVO NORDISK | NA |
Apr, 2037
(11 years from now) | |
| US10888605 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US11752198 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US12214017 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Aug, 2038
(12 years from now) | |
| US12029779 | NOVO NORDISK | Semaglutide in medical therapy |
Oct, 2038
(12 years from now) | |
| US12551536 | NOVO NORDISK | NA |
Oct, 2038
(12 years from now) | |
| US11318191 | NOVO NORDISK | GLP-1 compositions and uses thereof |
Feb, 2041
(14 years from now) | |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method of weight reduction via subcutaneous administration; Reduction of the risk of major cardiovascular events in subjects with cardiovascular disease and either obesity or overweight
Dosage: SOLUTION
How can I launch a generic of WEGOVY HD before its drug patent expiration?
More Information on Dosage
WEGOVY HD family patents
40. Yuviwel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906847 | ASCENDIS | Prodrug comprising a drug linker conjugate |
Apr, 2031
(5 years from now) | |
| US10835578 | ASCENDIS | Cnp Prodrugs With Large Carrier Moieties |
Jan, 2037
(10 years from now) | |
| US11154593 | ASCENDIS | Cnp Prodrugs With Large Carrier Moieties |
Jan, 2037
(10 years from now) | |
| US11224661 | ASCENDIS | Controlled-Release Cnp Agonists With Increased Nep Stability |
Jan, 2037
(10 years from now) | |
| US11311604 | ASCENDIS | Controlled-Release Cnp Agonists With Low Npr-C Binding |
Jan, 2037
(10 years from now) | |
| US11389510 | ASCENDIS | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity |
Jan, 2037
(10 years from now) | |
| US11413351 | ASCENDIS | Cnp Prodrugs With Carrier Attachment At The Ring Moiety |
Jan, 2037
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389511 | ASCENDIS | Controlled-Release Cnp Agonists With Reduced Side-Effects |
Jan, 2037
(10 years from now) | |
| US12083182 | ASCENDIS | Controlled-Release Cnp Agonists With Increased Nep Stability |
Jan, 2037
(10 years from now) | |
| US12156917 | ASCENDIS | Cnp Prodrugs With Carrier Attachment At The Ring Moiety |
Jan, 2037
(10 years from now) | |
| US12239689 | ASCENDIS | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity |
Jan, 2037
(10 years from now) | |
| US12377133 | ASCENDIS | Dry Pharmaceutical Formulations Of Cnp Conjugates |
Nov, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-516) | Feb 27, 2033 |
Drugs and Companies using NAVEPEGRITIDE ingredient
Market Authorisation Date: 27 February, 2026
Treatment: Increase of linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses
Dosage: POWDER
More Information on Dosage
YUVIWEL family patents